130 unknown, 106 completed, 49 recruiting, 27 not yet recruiting. 263 Phase 2, 56 Phase 3, 51 Phase 1, 10 Not applicable, 7 Phase 4.
Follow S 1 (combination): new trials by email Literature Review of S 1 (combination) trials Research Report on S 1 (combination)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Rilvegostomig Alpha, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-09 |
| Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma Standard Treatment Group: SOX regimen for up to 6 cycles Oxaliplatin: 130 mg/m², i.v., D1, Q3W; S-1 (Tegafur-Gimeracil-Oteracil Potassium): Oral administration: 40 mg per dose for BSA < 1.25, 50 mg pe, Experimental Immunotherapy Group: Phase I: Combination Therapy Period (First 3 Cycles) Oxaliplatin: 130 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W), for 3 cycles. Serplulimab: 300 mg, i - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 108 | 2026-09-01 | 2026-08-19 |
| Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Serplulimab and Bevacizumab injection, FOLFIRINOX/NALIRIFOX, S-1 - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Shanghai General Hospital, China | 34 | 2026-08-01 | 2026-07-29 |
| Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy - NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | BOE Technology Group Co., Ltd. | 42 | 2026-08-01 | 2026-08-26 |
| Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma propranolol, Toripalimab, Oxaliplatin - Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol | Phase 1 / Phase 2 | Not yet recruiting | Ting Liu | 49 | 2026-08-01 | 2026-07-27 |
| Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma serplulimab, Placebo - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Recruiting | National Cancer Center, Japan | 136 | 2026-07-15 | 2026-08-05 |
| Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer Multimodal Thermal Therapy (MTT) System, KRAS G12V mRNA Vaccine, Sintilimab - Pancreatic Ductal Adenocarcinoma, Liver Neoplasms | Phase 2 | Not yet recruiting | Ruijin Hospital | 20 | 2026-07-13 | 2026-08-04 |
| HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer Hyperthermic Intraperitoneal Chemotherapy, Serplulimab, S-1 - Locally Advanced Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 48 | 2026-07-13 | 2026-10-22 |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zanidatamab, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 46 | 2026-07-01 | 2026-07-06 |
| Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study Postoperative radiotherapy, Capecitabine or S-1 - Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 92 | 2026-06-16 | 2026-06-24 |
| Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction Iparomlimab and Tuvonralimab Injection (QL1706), S-1, Oxaliplatin - Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Yongxu Jia | 34 | 2026-05-10 | 2026-09-09 |
| Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer Adebrelimab plus S-1 and oxaliplatin, Adebrelimab blank preparation plus S-1 and oxaliplatin. - Locally Advanced Gastric or Gastroesophageal Junction Cancer | Phase 3 | Recruiting | Shanghai Shengdi Pharmaceutical Co., Ltd | 874 | 2026-05-07 | 2026-05-13 |
| SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis SHR-1701, Capecitabine, S-1 - Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 60 | 2026-04-24 | 2026-07-23 |
| Adebrelimab Plus S-1 for Resected Cholangiocarcinoma Adebrelimab, S-1 - Cholangiocarcinoma, Biliary Tract Cancer | Phase 2 | Not yet recruiting | Xingjun Guo | 40 | 2026-04-21 | 2026-05-01 |
| Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma Tislelizumab, LM-302 and S-1, Tislelizumab combined with oxaliplatin and S-1 - Gastric or Esophagogastric Junction Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 88 | 2026-04-21 | 2026-05-06 |
| LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study LM-302, S-1, paclitaxel, LM-302, Cadonilimab, S-1, paclitaxel - Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer | Phase 2 | Recruiting | Ruijin Hospital | 74 | 2026-04-17 | 2026-04-29 |
| SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer SHR-1701, apatinib, S-1 & Oxaliplatin - Gastric Adenocarcinoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 80 | 2026-04-03 | 2026-07-16 |
| Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma Sintilimab, Bevacizumab, Oxaliplatin - Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 46 | 2026-04-01 | 2026-04-07 |
| Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial Bevacizumab+nab-paclitaxel+tegafur gimeracil oteracil potassium capsule (S-1) - Biliary Cancer Metastatic | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 32 | 2026-02-23 | 2026-07-22 |
Showing 20 of 357. Sign in to see all of them.
Stomach Neoplasms (138) · Pancreatic Neoplasms (37) · Biliary Tract Neoplasms (19) · Esophageal Neoplasms (19) · Colorectal Neoplasms (18) · Esophageal Squamous Cell Carcinoma (12) · Cholangiocarcinoma (11) · Neoplasm Metastasis (10) · Carcinoma, Non-Small-Cell Lung (8) · Adenocarcinoma (7) · Gastrointestinal Neoplasms (6) · Colonic Neoplasms (5) · Nasopharyngeal Carcinoma (5) · Gallbladder Neoplasms (4) · Head and Neck Neoplasms (4)
Fudan University (22) · Chinese Academy of Medical Sciences (14) · Ruijin Hospital (12) · Sun Yat-sen University (12) · The First Affiliated Hospital with Nanjing Medical University (12) · Taiho Oncology, Inc. (9) · Tianjin Medical University Cancer Institute and Hospital (9) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · Chinese PLA General Hospital (8) · Taiho Pharmaceutical Co., Ltd. (8) · Peking University (7) · Zhejiang Cancer Hospital (7) · Hallym University Medical Center (6) · Hokkaido Gastrointestinal Cancer Study Group (6) · Kansai Hepatobiliary Oncology Group (6)
China (216) · Japan (47) · South Korea (43) · Taiwan (16) · United States (10) · France (7) · Germany (7) · Italy (7) · Spain (6) · Brazil (5) · Netherlands (4) · Poland (4) · Australia (3) · Belgium (3) · Denmark (3)
Dae Young Zang, MD, PhD (5) · Fabio Benedetti, MD (3) · Jiren Yu (3) · Lin Shen, Professor (3) · Masahiro Asaka, MD, PhD (3) · Project Leader (3) · Taiho Central (3) · Zhenggang Zhu (3) · Binghe Xu, M.D. (2) · Etsuro Hatano, MD, PhD (2) · Guoli Li, M.D. (2) · Hiroaki Nagano, MD, PhD (2) · Lin Yang, MD (2) · Min-Hee Ryu, MD, PhD (2)
PMID 35219300, PMID 21444866, PMID 23547081, PMID 25477010, PMID 26808342, PMID 31765987, PMID 34351356, PMID 37195667, PMID 10581077, PMID 11556297, PMID 15928658, PMID 16822992, PMID 17978289, PMID 18553228, PMID 19331206, PMID 21183517, PMID 21365500, PMID 22189752, PMID 22554343, PMID 23062232, PMID 23497365, PMID 23664139, PMID 23665950, PMID 24131140, PMID 24366758, PMID 24514954, PMID 24618998, PMID 24662266, PMID 24737677, PMID 24889903, PMID 24942277, PMID 25273077, PMID 25424120, PMID 25612635, PMID 25943068, PMID 26109630, PMID 26158159, PMID 26216386, PMID 26385385, PMID 26412280, PMID 26884585, PMID 27076940, PMID 27156933, PMID 27157491, PMID 27776843, PMID 27909037, PMID 27913881, PMID 28102259, PMID 28383633, PMID 28457713
2023 (2), 2014 (1), 2016 (1), 2018 (1)